Efficacy of canakinumab in mild or severe COVID ‐19 pneumonia

ConclusionIn hospitalized adult patients with mild or severe non ICU COVID ‐19, canakinumab could be a valid therapeutic option. Canakinumab therapy causes rapid and long‐lasting improvement in oxygenation levels in the absence of any severe adverse events.

Source: Immunity, Inflammation and Disease - January 19, 2021 Category: Allergy & Immunology Authors: Falasca Katia, Di Penta Myriam, Claudio Ucciferri, Antonio Auricchio, Marta Di Nicola, Michele Marchioni, Celletti Eleonora, Sabatini Emanuela, Francesco Cipollone, Jacopo Vecchiet Tags: ORIGINAL RESEARCH Source Type: research